|
N30 Pharmaceuticals Announces Publication of S-Nitrosoglutathione Reductase …
Marketwire (press release) The report focuses on the lead chemical series which generated N30 N6022, a first in class GSNOR inhibitor currently in Phase 1b/2a trials for the treatment of asthma. GSNOR breaks down S-nitrosoglutathione (GSNO), and as such is an important regulator … |
View full post on asthma – Google News